BOSTON, July 31, 2024 /PRNewswire/ -- Recently, Shanghai Medicilon Inc. ('Medicilon') and Jiangsu Hengrui Pharmaceuticals Co., Ltd. ('Hengrui Pharma') reached a strategic collaboration agreement. The cooperative efforts will focus on preclinical evaluation of new drug modalities, particularly ADCs, small nucleic acids, and CGT (cell and gene therapy) drugs. The goal of this partnership is to advance the innovation of the Chinese pharmaceutical industry to compete on an international level.